Your reps are covering their territories. Your clinical champions are trained. Market access is approved, the reimbursement pathway mapped, and by every internal adoption metric this is going well.
Procedure counts are flat.
You've been focused, entirely and understandably, on the clinician channel. Regional training days, centres of excellence, embedded clinical support, and twelve-minute supplier access windows navigated with genuine precision. The team is good. The execution is professional.
But seventy-seven percent of patients research their condition online before they see a specialist. The UK self-pay market has grown 10% year on year for three consecutive years. 820,000 self-funded private admissions last year.
The patient is already searching. They're landing somewhere. The question is whether they're landing with you.
What Most Commercial Teams Do
The standard response to flat procedure volumes is to look at the clinician channel more carefully.
More training days. Tighter territory coverage. Better data on which consultants are using the product and which aren't yet. Perhaps a clinical panel. A congress symposium. A KOL engagement programme that takes twelve months to build and produces a paper medical affairs can cite for the following three years.
This is not a stupid response. The clinician channel works. It is also the channel most commercial teams know how to build, fund, and measure. You can track it. You can report on it. You can connect it to adoption rates with reasonable confidence.
So when procedure counts disappoint, the instinct is to push harder on the thing that's measurable. More rep visits. Better targeting. Tighter coverage of the high-volume centres.
The patient channel gets a different treatment. Most commercial teams aren't measuring it. And most aren't measuring it because they've never built it.
The reasons vary. In some organisations, legal was asked once whether patients could be targeted, gave a cautious answer, and the question was never asked again. (The cautious answer became policy. The policy became silence.) In others, there simply isn't a clear owner. Medical affairs isn't sure it's their territory. Marketing isn't sure it's compliant. Commercial leadership is focused on the metric in front of them.
The result is the same: a conversation with the patient that either doesn't happen, or happens so late in the decision process that it barely qualifies as a conversation.
Why the Clinician Channel Has a Limit
The clinician-first commercial model assumes something that is decreasingly true: that the patient arrives at the GP, gets referred, and follows the pathway the sales team has carefully opened.
In high-volume NHS surgical settings, this largely holds. But the self-pay market has changed the picture considerably. And even within NHS pathways, patient behaviour upstream of that first GP consultation has shifted.
Consider what happens before a patient with persistent knee pain contacts anyone in the healthcare system.
The average person in that position has been managing pain without surgical intervention for three to five years. Physiotherapy. Paracetamol. The "let's monitor it" appointment that produces no change. They've been told to keep going. They've nearly given up on the idea that anything is going to fix it.
They are not, typically, walking into the GP surgery and asking for a surgical referral. They're searching online, usually late at night, for whether there's anything else they haven't tried. If your product is the answer to that search, but your company isn't in the conversation, they don't find you. They might find a forum. They might find a competitor's patient page. They might find nothing useful and give up for another year.
The GP referral model assumes the patient has already decided to act. Many haven't. The ones who have are often doing their own research before they contact anyone.
This matters more now than it did ten years ago. The UK self-pay market growing at 10% year on year is not driven by patients who sit in a waiting room and do whatever they're told. It's driven by people who researched, decided, and paid. The commercial team that waits for the GP to generate that patient is, in that market, waiting for something that doesn't reliably happen.
The other problem is structural. Clinical champions are excellent at clinical adoption. They perform procedures well. They train their teams. They advocate for the technology within their network.
They don't, as a rule, run patient acquisition campaigns. They weren't hired to, they aren't resourced for it, and even the most enthusiastic ones have finite capacity. The company that waits for forty clinic partners to generate their own patients is waiting for a machine that, in most cases, doesn't exist.
What's Actually Happening
The patient conversation is happening without most healthcare commercial teams in it.
Patients are searching, reading, comparing, and deciding. The questions they're asking are accessible. The search volume is measurable. The content gap between what they need and what healthcare companies are providing is, in most specialties, substantial.
(Ask me how I know.)
Most medical device and pharmaceutical companies have extensive resources dedicated to HCP communication. Clinical data, white papers, training materials, congress content, regulatory-approved messaging houses. The patient-facing equivalent either doesn't exist, or exists as a brief paragraph on a product landing page that was written several years ago and last reviewed by legal some time after that.
Meanwhile, patient advocacy groups, private hospital marketing teams, and occasionally competitors have started filling that space. Not always well. But they're there, and they're in the conversation at the moment patients are most likely to decide.
The shift that's happened isn't that patients became more demanding or more digital. They were always going to research. The shift is that the tools to reach them at the moment of consideration have become affordable and measurable in a way they weren't a decade ago.
A campaign reaching 40-55 year olds managing persistent joint pain in a specific geography, at the moment they're most likely to be searching for alternatives to conservative management, is not science fiction. It's not particularly expensive by the standards of a regional training day.
It just requires the commercial team to think about patient acquisition as a channel, not as an afterthought.
A Different Approach
The starting point isn't a brief. It's a question.
Which specific commercial outcome are you trying to drive? More new patients into existing clinic partners? Shorter time-to-treatment in an underperforming geography? Increased procedure volume in a cohort where clinical adoption is high but patient flow is the bottleneck?
The campaign only exists to serve a commercial objective. That clarity changes what gets briefed. Often it eliminates work that would otherwise happen. (Still working on keeping this discipline ourselves, if I'm honest. The creative tends to start before the objective is clear more often than anyone would like.)
Once the objective is clear, the second step is to build content from the patient's perspective, not the product's.
A professor reviewing our patient materials was direct about it: patients don't want to know about the product. They want to know what's going to happen to them. Those are different briefs. The instinct, after years of building HCP-facing content, is to default to clinical data and mechanism of action.
A patient who has spent three years managing persistent pain and is tentatively considering whether surgery might be an option doesn't need to understand the mechanism of action. They need to know what the appointment looks like. What recovery feels like. Whether other people like them have done this and whether it worked. Content that answers those questions, rather than explaining the product, performs differently.
It is also, sometimes, easier to get through regulatory review. Because you're not making clinical efficacy claims. You're helping someone understand their options. Those are different conversations with a different risk profile.
The approval pathway moves faster when you've built the framework before you need it. The companies that move quickly on patient-facing content have almost always done one thing differently: they've pre-approved a bank of fifteen to twenty patient-facing claims covering their main scenarios before the brief arrives. Each claim has its evidence. Each has regulatory sign-off. When creative starts, you're drawing from an approved pool rather than restarting the review cycle on every single piece.
Front-loaded investment. Speed comes later.
The fourth thing, the thing most commercial teams skip because it seems unsexy, is to map where current patients are actually coming from. Not in general. Specifically. If you can't tell me which referral stream generated your last hundred procedures, you cannot tell me which channel deserves the next investment. And most commercial teams cannot tell me.
That mapping exercise rarely takes more than a few weeks. It almost always changes the brief that follows.
Mind you, most teams know this is the right starting point and still don't do it. The brief is already written. The agency is on standby. There's a launch date. The map gets skipped, and six months later nobody can quite explain why the campaign didn't move the numbers.
What Happens When You Do This Well
A commercial team managing a minimally invasive treatment for persistent joint pain had forty clinic partners operating across the UK. Twelve months into the launch, procedure counts were flat.
The initial diagnosis was a clinician engagement problem. More training. Better rep coverage. Stronger KOL support. The response was professionally executed. Awareness moved. Capability improved.
Procedure counts remained flat.
When the patient journey was mapped properly, the problem came into focus. The clinics were seeing patients who arrived. They were not generating the patients who needed to arrive.
The average patient appropriate for this treatment had been managing symptoms conservatively for three to four years. They weren't being referred. Their GPs were managing pain with conservative approaches and had no particular prompt to escalate. The patients themselves weren't asking for a referral because they didn't know one was possible.
What changed was a targeted digital campaign aimed at the 40-55 cohort managing persistent joint pain in geographies where clinic coverage already existed. The campaign didn't explain the product. It answered the questions patients were already asking: whether something could actually help, what the pathway looked like, what other people in a similar position had found.
Over the following six months, referral rates into those forty clinics increased by roughly a third.
The clinicians hadn't changed. The product hadn't changed. The commercial team had started a conversation the patient needed someone to start.
Where to Begin
Before any brief. Before any conversation with regulatory. Before any creative.
Map where your current patients are coming from. Ask ten clinic partners how their patients find them. The answers will vary significantly, and they will tell you more about your commercial model than six months of additional rep visits.
Talk to your product or device supplier's marketing team before you build your own infrastructure. The stronger commercial partners have already built patient marketing support for clinic networks: co-branded campaigns, patient education content, digital targeting tools. If your supplier has this and you're not using it, you're paying to build something that already exists. If they don't have it, that's useful market intelligence about where the category is.
Look at search intent in your target geographies. The patients searching for alternatives to conservative management of their condition are online right now. Their searches are measurable. The content gap between what they're looking for and what's available from companies in your space is, in most cases, substantial.
Build one piece of patient-facing content that answers the question patients ask before they book. Not a company overview. Not a product explainer. The question they're actually asking: what happens if I do this? That piece, done well, does more commercial work than most companies realise.
Involve regulatory early. Not at the end, when creative is done and timelines are committed. Bring them in at the claim-building stage, before the brief. Let them help define what can and can't be said. The companies that move fastest on patient content are the ones where regulatory is a collaborator from the start, not a gatekeeper at the finish.
None of this requires a large budget. It requires a decision that the patient channel is worth building.
The Real Stakes
Patient marketing isn't a campaign problem. It's a question of whether the people who need treatment are finding it.
The self-pay market is growing because patients are starting to make their own decisions. 820,000 self-funded private admissions last year. Three to five years of managed pain before most of those decisions got made. Patients who very nearly gave up before they found something that worked.
The channel is real. The conversation is happening. The only question is whether you're in it, or whether someone else is.
What next?